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Abstract
DNA damage has been associated with prostate cancer risk. Men who were referred for initial prostate biopsy for
elevated prostate-specific antigen or abnormal digital rectal examination are often found with no cancer but have a
higher risk of developing prostate cancer than the general population of men in their lifetime. In this study, we
investigated whether DNA damage is one of the factors that predispose these men referred for prostate biopsies
to a higher risk of prostate cancer. We found significantly elevated levels of 8-oxo-2-deoxyguanosine immuno-
reactivity in the prostates of the referred men (n = 50) in comparison to the control prostates of men (n = 32)
with no indication for referral for prostate biopsy. Twelve of these control men were healthy middle-aged men
and 20 of them were older men whose conditions were diagnosed with bladder cancer but with normal serum
prostate-specific antigen and digital rectal examination and no evidence of prostate disease. In all the 8-oxo-2-
deoxyguanosine–positive prostates, we detected phosphorylation of the ataxia telangiectasia mutated kinase
and expression of the immune-stimulatory molecule MIC in the prostate epithelium. These data suggest that: 1)
oxidative DNA damage has occurred in the “referred” but pathologically normal prostates, indicating that these pros-
tates may be subjected to genomic instability and eventually neoplastic transformation; 2) in response to DNA dam-
age, two surveillance pathways, represented by ataxia telangiectasia mutated phosphorylation and induction of
the NKG2D ligand MIC, were activated to prevent tumorigenesis.
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Introduction
The tumor suppressor ATM (ataxia telangiectasia mutated) is consti-
tutively expressed but generally inactive in normal human tissues ex-
cept in specialized cell types, for example, germ cells and lymphocytes
[1]. In response to genotoxic insults, human cells, if not ATM-
deficient, immediately activate the ATM protein kinase by autopho-
sphorylation to initiate DNA-damage responses [2,3]. Thus, activation
of ATM signifies the occurrence of DNA damage in cells. Activated
ATM can interact with multiple pathways in response to DNA dam-
age and serves as a “sensor” of oxidative stress to maintain DNA integ-
rity [4,5]. It is well understood that ATM respond to severe DNA
damage such as double-strand breaks (DSBs) by immediate phosphory-
lation of downstream target phospho-histones [6,7]. ATM can also re-
spond to more subtle forms of DNA damage, such as single-strand
base modification, among which, the oxidation of guanine, 8-oxo-2-
deoxyguanosine (8-oxo-dG), is the major lesion [5,8,9]. Although com-
plicated pathways are involved in ATM-mediated DNA-damage re-
sponses [10], phosphorylation of ATM results in either activation
of cell cycle checkpoints to facilitate DNA repair or induction of
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p53-mediated apoptosis of severely damaged cells [1,2]. Activation of
ATMhas been shown in preneoplastic lesions of human breast, bladder,
and colon and thus suggested to be a very early DNA damage surveil-
lance mechanism to protect against transformation [11–14].
Recent studies indicate that exposure of nontransformed cell lines
to genotoxic stresses can induce expression of the ligands for the im-
mune receptor NKG2D through the same DNA damage response
pathway as that activates ATM [15]. NKG2D is an activating recep-
tor expressed by human natural killer (NK) cells, γδ T cells, CD8 T
cells, and some activated CD4 T cells [16,17]. This finding revealed
a possible new dimension to the mechanisms of early surveillance
against tumorigenesis. In humans, the stress-induced MHC I chain–
related molecules A and B (MICA/B, generally termed MIC) are the
most frequently studied human NKG2D ligands [17]. MIC is often
found expressed by human epithelial tumors but generally absent in
normal tissues [18]. Engagement MIC to NKG2D can activate innate
NK cell antitumor immunity as cytotoxicity and cytokine production
[19]. Induced expression of MIC has been proposed to be one of the
innate protective mechanisms for the host in response to epithelial
transformation [16,17]. Conversely, tumor cells can shed MIC and
the resulting soluble form of MIC (sMIC) can impair host immunity,
which is suggested to be one of the mechanisms of tumor immune
evasion and progression [20].
DNA damage or failure of DNA damage surveillance has been as-
sociated with increased prostate cancer risk [21–23]. Several clinical
studies have indicated that men who were referred for prostate biopsy
because of elevated prostate-specific antigen (PSA > 4.0 ng/ml) or ab-
normal digital rectal examination (DRE) results but no evidence of
cancer on biopsy have a higher incidence of developing prostate cancer
than men in general population [24–27]. It has been suggested that
there are preneoplastic changes in the “referred” prostate, which may
be associated with increased risk of prostate cancer [28]. Here, we for-
mulated the hypotheses that biological changes, such as DNA damage,
have occurred in the “referred” prostates to predispose these men to in-
creased risk of prostate cancer and that early tumor surveillance against
these changes may form a barrier to tumorigenesis. To address these
assertions, we examined oxidative DNA damage and responses to
DNA damage, the ATM phosphorylation and the induction of MIC
expression, in these “referred” prostates.
Materials and Methods
Patient and Sample Demographics
The collection and the use of tissue specimens and of relevant
clinical information were approved by the University of Washington
Institutional Review Board. Formalin-fixed and paraffin-embedded
“referred” prostate needle core biopsies (n = 50) were obtained from
the outpatient Urology Clinics at the Veterans Affair Puget Sound
Health Care System. These biopsies were from men who had either
an elevated serum PSA (>4.0 ng/ml) or an abnormal DRE results and
had not undergone a previous prostate biopsy. All men underwent a
12-core biopsy protocol of the peripheral zone of the prostate. Patho-
logical examination of the biopsies showed no histologic evidence of
prostate cancer or prostatic intraepithelial neoplasia based on inde-
pendent review by two pathologists experienced in prostate cancer.
Two biopsy cores were chosen for this study.
Two groups of “healthy” prostate biopsies were used as normal or
negative controls. The first group consisted of prostate biopsies from
healthy middle-aged men (n = 12; median age, 42 years) with a se-
rum PSA ≤2.5 ng/ml and a normal DRE result who had biopsies as
part of a separate investigation [29,30]. The other group consisted of
prostate specimens from aged men whose conditions were diagnosed
with bladder cancer but with a serum PSA <4.0 ng/ml (n = 20; me-
dian age, 62 years), a normal DRE result, and no evidence of prostate
cancer in microscopic examination of the prostate.
Lastly, we constructed tissue microarrays composed of prostate ad-
enocarcinoma (n = 19; median age, 64 years) from men undergoing
radical prostatectomy for clinically localized prostate cancer (Gleason
grades 5‐7) for comparison.
Immunohistochemistry
To evaluate DNA damage responses, we performed immunohisto-
chemistry (IHC) staining of the prostate specimens using the follow-
ing IHC-specific antibodies: anti–8-oxo-dG (Clone N45.1; Japan
Institute for Control of Aging [31,32]), anti-ATM (Ab-8; NeoMarkers,
Fremont, CA), monoclonal anti-Ser 1981-phosphorylated-ATM
(pS-ATM) antibody (Rockland Immunochemicals, Gilbertsville, PA
[12,13]), and MHC I chain–related molecule (MIC)–specific rabbit
polyclonal antiserum H-300 (Santa Cruz Biotechnology Inc., Santa
Cruz, CA [24]). Rabbit anti-phospho-H2AX antibody was from cell
signaling (Danvers, MA).
Indirect IHC on formalin-fixed, paraffin-embedded tissues sections
or microarrays was performed as previously described [33], using
Vectastin Elite Kit (Vector Laboratories, Burlingame, CA). Briefly,
slides containing sections of prostate lesions were dewaxed and rehy-
drated. After antigen retrieval procedure, endogenous peroxidase activity
was quenched. After being blocked with 1.5%normal goat serum, slides
were incubated with specific antibody for 1 hour followed by sequential
incubation with biotinylated secondary antibody, peroxidase-labeled
avidin, and diaminobenzidine/hydrogen peroxide chromogen substrate.
Some slides were counterstained with hematoxylin before mounting.
For the negative control, species-matched immunoglobin controls
(Vector Laboratories) were used instead of the primary antibody.
Evaluation of Immunohistochemistry Staining
The intensity of specific staining was double-blind graded on a scale
of 1 to 3 (1 = weak staining, 2 = moderate staining, and 3 = strong
staining). A semiquantitative score on a 10% increment scale ranging
from 0 to 100% was used to assess the percentage of stained cells of
the intensity. Approximately 500 cells were analyzed for each case. The
final composite staining score for immunostaining was based on the
intensity of staining (1, 2, or 3) multiplied by the percentage of
immunopositive cells (0‐100). The maximum composite score is 300.
Statistical Analysis
Statistical analyses were performed using STATA (College Station,
TX). The composite staining scores for 8-oxo-dG, pS-ATM, and
MIC between subject groups were compared using analysis of vari-
ance with a Scheffe correction for multiple comparisons. Paired t-tests
with a Bonferroni correction were performed for significance. For all
comparisons, a P value < .05 was considered statistically significant. All
P values are 2-tailed.
Results
The Referred and Control Subjects
The basic clinical characteristics of the referred and control subjects
are given inTable 1.There was no significant difference in age or prostate
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size between the referred subjects and the aged control subjects. How-
ever, the referred subjects have significantly higher levels of serum PSA
than the control aged subjects (P < .05). One third of the middle-aged
control subjects were under androgen-suppression treatment for 4 weeks
because of participating in an androgen-suppression investigation
[29,30]. These subjects had reduced serum and intraprostatic tissue
levels of testosterone (T) and dihydrotestosterone (DHT) at the time
of biopsy [30]. However, the short-term androgen suppression did not
affect the current study results.
Oxidative DNA Damage in the “Referred” Prostates
Extensive observations suggest that reactive oxygen species may
cause accumulated DNA damage during aging, which contributes
to increased incidence of cancer [34]. We thus examined the levels
of oxidative DNA damage in the referred prostates. Fifty paraffin-
embedded “referred” prostate biopsy specimens were IHC-stained
with a monoclonal antibody specific to the oxidative DNA damage
marker, 8-oxo-dG [31,32]. Sections of prostate biopsies from 12
middle-aged healthy men and 20 age-matched older men who have
a PSA <4.0 ng/ml, a normal DRE result, and no evidence of pros-
tate cancer were used as negative controls. Of 50 “referred” prostates,
36 (74%) showed positive 8-oxo-dG immuoreactivity. In contrast,
8-oxo-dG immunoreactivity was not found in the prostates from
the 12 healthy middle-aged men and only found in 1 (5%) of 20
prostates from the control age-matched older men. The immuno-
reactivity of 8-oxo-dG was predominantly localized to the luminal
epithelium of the prostates (Figure 1, A and B). We also assessed
8-oxo-dG immunoreactivity in the prostate carcinomas as a comparison.
Nearly all the carcinomas from the 19 subjects showed strong 8-oxo-dG
immunoreactivity (Figure 1C).
We evaluated the level of 8-oxo-dG immunoreactivity in the epi-
thelium of these specimens using a semiquantitative method by mul-
tiplying the intensity of immunostaining with the percentage of
immunopositive cells (see details in Materials and Methods). 8-oxo-dG
immunoreactivity was significantly elevated in the “referred” prostate epi-
thelium compared with the two control groups (Table 2, P < .001) and
was significantly elevated in the carcinomas compared with the referred
prostates (Table 2, P < .01).
Reactive oxygen species can also cause DNA DSBs. We thus also
examined the level of DSBs in the referred prostates by IHC staining
with a specific antibody to phospho-H2AX [7]. Thirty-nine of the
referred prostates showed weak immunoreactivity of phospho-H2AX.
Neither the frequency nor intensity of phospho-H2AX immunore-
activity has correlation with the positivity of 8-oxo-dG in the referred
prostates (data not shown). These data suggest that single-strand DNA
base oxidative modification is the major form of oxidative DNA dam-
age in the referred prostates.
Cellular DNA Damage Surveillance in the “Referred” Prostate
Through Activation of ATM Kinase in the Epithelia
ATM kinase is a key regulator of biological response to DNA dam-
age [2], and activation of ATM by phosphorylation is one of the first
indications of cellular response to DNA damage [3]. To evaluate
ATM phosphorylation status in the “referred” prostates in response
to oxidative DNA damage, we first examined ATM expression in
these biopsies. ATM was constitutively expressed in all the prostate
tissues (Figure 2, A–C ). We next evaluated ATM phosphorylation in
these prostate biopsies using IHC with the monoclonal antibody
pS-ATM, which is specific to serine1981-phosphorylated-ATM
[12,13]. In the 50 “referred” prostate specimens, phosphorylation of
ATM was evident in the epithelium of 42 specimens (Figure 2E), in-
cluding the 36 specimens that are 8-oxo-dG–positive. Phosphorylation
of ATM was not seen in the middle-aged and only weakly seen in 1 of
20 of the older “control” prostate epithelium (Table 2 and Figure 2D).
In carcinomas, ATM immunostaining showed a great degree of
heterogeneity, which may be due to the heterogeneity of mutations
in the ATM gene [35]. Phosphorylation of ATM was seen in the epi-
thelium of all the specimens but with a high degree of heterogeneity in
intensity and reduced levels in most cells (Figure 2F ). This attenuated
or defective ATM activation has been suggested to be a cause of cancer
progression [36].
To further confirm that ATM was specifically activated in the “re-
ferred” prostates, we evaluated the level of ATM phosphorylation in
the epithelium of these specimens using a semiquantitative method
as described above. Phosphorylation of ATM in the “referred” pros-
tate epithelium was significantly elevated compared with the two
Figure 1. 8-oxo-dG immunostaining showing oxidative DNA damage in the referred prostates: (A) referred prostate, (B) age-matched
control prostate, (C) prostate carcinoma. The IHC-specific anti–8-oxo-dG antibody (Clone N45.1) was used. Original magnification, ×250.
Table 1. Clinical Characteristics of the Referred and Control Subjects.
Subject Group Referred
(n = 50)
Control Middle-aged
(n = 12)
Control Aged
(n = 20)
Age (years) 61.4 ± 5.9 42.7 ± 3.4 62.4 ± 6.7
PSA (ng/ml) 7.6 ± 7.1 <2.0 <4.0
Prostate volume (cm3) 40.4 ± 24.6 22.7 ± 4.2 35.6 ± 29.4
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control groups (Table 2, P < .001) and carcinomas (Table 2, P = .03).
Whereas the differences in the levels of ATM phosphorylation between
the “referred” biopsy and the carcinoma may be in part due to ATM
mutation and thus reduced ATM expression in the carcinomas [12]
(Table 2), the significantly elevated ATM phosphorylation in the “re-
ferred” specimens compared with the normal controls is not a result of
difference in ATM expression (Table 2). The normal and the “referred”
prostates expressed comparable levels of ATM protein (Table 2 and
Figure 2, A and B).
Systemic DNA Damage Surveillance by Induction of MIC
Expression in the Secretory Epithelial Cells
Gasser et al. [15] have shown that induced expression of MIC was
associated with DNA damage in cells. We thus examined MIC ex-
pression in these prostate biopsies. With a specific antibody to MIC,
we showed positive MIC immunoreactivity in the luminal secretory
epithelium of the “referred” prostate biopsies, which showed positive
to pATM (Figure 2H ). In comparison, all the middle-aged and 19 of
the 20 older healthy prostate glands were negative for MIC (Table 2
Figure 2. Immunohistochemistry staining showing activation of ATM and induction of MIC in the luminal epithelium of the represen-
tative “referred” prostate. ATM is constitutively expressed in the prostate (A–C). Phosphorylation of ATM is rare in the healthy prostate
(D) but evident in the “referred” prostate (E) and heterogenic in carcinomas (F). MIC expression is detected only where ATM was phos-
phorylated (G–I). Original magnification, ×200.
Table 2. Evaluation of 8-oxo-dG, ATM, pATM, and MIC Immunostaining in Prostate Epithelium.
Type of Prostates Composite Staining Scores*
8-oxo-dG pATM ATM MIC
Median Mean ± SD Median Mean ± SD Median Mean ± SD Median Mean ± SD
Healthy (middle-aged) 0 0 0 0 300 300.0 ± 0.0 0 4.8 ± 19.2
Healthy (aged) 0 5.2 ± 20.4 0 4.2 ± 18.4 300 300.0 ± 0.0 0 4.8 ± 19.2
referred 120 153.0 ± 103.2† 200 208.2 ± 58.7† 300 300.0 ± 0.0 185 197.5 ± 59.1†
Cancer 300 284 ± 48.4‡ 120 123 ± 42.1 170 172.6 ± 55.3 80 88.4 ± 37.5
*Composite score = staining intensity (1, 2, or 3) × percentage of positive cells (0-100). Maximum score is 300.
†Composite score is significantly higher in the referred than in the healthy (P < .001).
‡Composite score is significantly higher in carcinoma than in the referred (P < .01).
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and Figure 2G ). In the carcinomas, the luminal epithelia showed het-
erogeneity in MIC immuoreactivity (Figure 2I ). Overall, MIC ex-
pression was detected where phosphorylation of ATM was apparent.
To confirm the specificity of the anti-MIC antibody, we preabsorbed
the anti-MIC antibody with purified recombinant soluble MIC. No
MIC immune reactivity was yielded in any of the specimens (Figure 3),
thus confirming the specificity of the anti-MIC antibody.
We also assessed MIC expression in the epithelium of these speci-
mens using the semiquantitative method as described above. As
shown in Table 1, MIC expression was significantly elevated (P <
.001) in the “referred” prostate epithelium compared with either the
middle-aged or the age-matched normal controls. Although MIC was
prevalently expressed in the carcinomas, the level was significantly lower
when compared with the “referred” epithelium (P < .05). The reduced
level of MIC expression shown in the carcinomas is due to tumor shed-
ding of MIC as we have previously reported [33].
Correlation of MIC Expression with ATM Phosphorylation
Using simple regression analysis, we show that there is a signifi-
cant correlation of MIC expression and ATM phosphorylation in
the “referred” prostate epithelium (R = 0.99, P < .001; Figure 4A).
There was also a significant correlation between MIC expression and
ATM phosphorylation in the carcinomas (R = 0.78, P < .001;
Figure 4B). Together, these results demonstrate that, in the “referred”
prostate, induction of MIC expression is correlated with ATM phos-
phorylation, presumably a manifestation of the cellular response to
DNA damage.
Figure 3. Peptide blocking demonstrating specificity of anti-MIC
antiserum. (A–E) MIC immunoreactivity with the rabbit anti-MIC
anti–serum H-300 in various prostate specimens. (A and B) No posi-
tive MIC immunoreactivity was seen in the healthy prostate epithe-
lium. (C and D) Different intensity of MIC immunoreactivity in the
“referred” prostate epithelium. (F–J) No MIC immunoreactivity
was seen in any of the specimens when the anti-MIC antibody
was preabsorbed with 5 ng/μl purified sMICA. A and F are frozen
sections. The rest are paraffin-embedded sections. Original magni-
fication, ×200.
Figure 4. Correlation of MIC expression with ATM phosphorylation.
(A) Significant correlation of ATM phosphorylation and MIC expres-
sion in the prostate epithelium of the “referred” men, R = 0.99, P <
.001. (B) A lesser degree but still significant correlation of ATM
phosphorylation and MIC expression in the prostate carcinomas,
R = 0.78, P< .001. ATM phosphorylation and MIC immunostaining
were evaluated using a semiquantitative composite score method
as described in the Materials and Methods section. Data were ana-
lyzed using Pearson’s correlation test.
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Discussion
We have shown that two DNA damage response pathways, as indi-
cated by phosphorylation of ATM kinase and expression of the stress-
induced MIC, are activated in most (84%) of the “referred” prostate
epithelium. Among these prostates, a high percentage (36/42) expressed
an oxidative DNA damage phenotype as indicated by oxidative modifi-
cation of guanine. These manifestations are absent or rare in healthy
prostates. Our data indicate that genomic damage, predominantly
single-strand DNA base oxidative modification, has occurred in the epi-
thelium of these histologically normal but “referred” prostates.
DNA damage, caused by oxidative stress and/or free radical, has been
associated with an increased cancer risk [21–23]. It has been reported
that 42% of men aged 55 to 80 years exhibited a DNA-damaged phe-
notype in the prostate [23]. Our data suggest that DNA damage, largely
due to oxidative stress as indicated by 8-oxo-dG, has occurred in the
prostate of a majority of men referred for prostate biopsy in our insti-
tution.We have no evidence that our referral pattern for prostate biopsy
is different from that of other academic institution. However, studies
from other institutions suggest that 25% to 40% of these “referred”
men will be expected to have their conditions diagnosed with prostate
cancer in future biopsies [24–27]. The lower incidence of prostate
cancer development in contrast to the high incidence of DNA damage
of the “referred”men may be due to activation of two surveillance path-
ways as our study has indicated, which prevents or delays the develop-
ment of cancer (Figure 5). The primary pathway is phosphorylation of
ATM, which initiates the DNA repair or apoptosis. The secondary
pathway alerts the immune system by inducing the expression of
the immune stimulatory molecule MIC and potentially activating
NK cell immunity to eliminate cells with genomic damage and prevent
tumorigenesis. We speculate that, in some men, mutations accumulate
in the DNA damage response pathways during aging, such as pTEN,
p53, CHEK, and so on [37], thus unscheduled cell replication would
likely occur, which will ultimately result in genomic instability and
tumorigenesis. In fact, this speculation is supported by our current
data showing the elevated level of DNA damage and impaired activa-
tion of ATM in the carcinomas. In addition, tumor cells may shed
MIC, which can lead to the failure of MIC-induced innate immune
surveillance [33].
Figure 5. Proposed etiology of DNA damage in the “referred” prostate biopsies and prostate cancer risk. In response to DNA damage in
the prostate, cellular and systemic tumor surveillance pathways could be initiated to prevent tumorigenesis or cancer development.
Protection at cellular level is through activation of ATM to initiate DNA repair or apoptosis of damaged cells. Protection at systemic
level is through the induction of MIC expression to alert of NK cell–mediated innate immunity. In the incidence of accumulation of
mutations in DNA repair or apoptosis pathways, genomic instability will occur and lead to prostate tumorigenesis. Compromised NK
cell function will enable tumor immune evasion and facilitate cancer development.
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Before this report, MIC was only shown to be expressed by trans-
formed cells, either in some viral-infected cells or in tumor cells. Our
data demonstrate that MIC can be detected in preneoplastic human tis-
sues where DNA damage has occurred. This suggests that MIC is un-
likely to be a tumor-specific biomarker. In fact, we show that the level of
MIC expression correlates with ATM phosphorylation in tissues, sug-
gesting that induction of MIC expression may serve as a general DNA
damage marker and signify a preneoplastic biological change in tissues.
Our study has several limitations. This is a clinical observation
study designed to generate associations with plausible biologic me-
chanisms related to carcinogenesis. Because prostate cancer is a slowly
developing disease, we do not have lifetime clinical follow-up data of
the study subjects. Thus, our findings can only be used as preneoplastic
markers to suggest potential cancer risk and cannot be powered to pre-
dict future cancer diagnosis.
In summary, our data indicate that, although the biopsy-based histo-
logical features may not identify a malignancy, genomic stress such as
DNA damage has occurred, which may predispose the prostate to neo-
plastic transformation. In response to the DNA damage, activation of
cellular DNA repair pathway and induction of the immune stimulatory
MIC expression may form barriers to prevent cancer development.
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